Plus plenty of catch-up, including a spate of analyses on the IRA's $2,000 OOP cap
Plus it's all about DTC today, with Lilly offering Zepbound at a low self-pay price via LillyDirect and Pfizer launching PfizerForAll
And Novo's CEO goes on NBC with messages likely to be tested by Bernie Sanders next month
And Reuters is joining us in thinking about the next round of price controls
And the Business Group on Health's employer survey shows nervousness over drug prices ... and contracting arrangements
So we have a flood of items on the IRA, plus a great visual on generic meds, a PDAB mention, and some data on pseudo-pharma companies
And Harris puts her marker down on drug-price policy
Plus some news on obesity, benefit design, and lawsuits that might otherwise fall through the cracks
There's a lot to dissect ...
And did you catch Mark Cuban on The Daily Show?
Plus a thoughtful Health Affairs Forefront piece on how to improve the IRA from V-BID's Mark Fendrick
Plus a new-drug approval release that sets a new standard for talking price and value
